JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Glaukos Corp

Închisă

SectorSănătate

88.18 0.79

Rezumat

Modificarea prețului

24h

Curent

Minim

84.44

Maxim

89.28

Indicatori cheie

By Trading Economics

Venit

15M

-18M

Vânzări

1.2M

107M

Marjă de profit

-17.012

Angajați

995

EBITDA

1.6M

-21M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+48.25% upside

Dividende

By Dow Jones

Următoarele câștiguri

3 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

69M

5.4B

Deschiderea anterioară

87.39

Închiderea anterioară

88.18

Sentimentul știrilor

By Acuity

19%

81%

38 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Glaukos Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 21:42 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug. 2025, 21:21 UTC

Câștiguri
Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug. 2025, 21:30 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 21:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug. 2025, 21:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss $938M >RIG

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug. 2025, 20:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug. 2025, 20:15 UTC

Câștiguri

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug. 2025, 20:13 UTC

Câștiguri

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug. 2025, 20:09 UTC

Câștiguri

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug. 2025, 20:06 UTC

Câștiguri

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparație

Modificare preț

Glaukos Corp Așteptări

Obiectiv de preț

By TipRanks

48.25% sus

Prognoză pe 12 luni

Medie 127.73 USD  48.25%

Maxim 165 USD

Minim 92 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGlaukos Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

11

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

87.61 / 93Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

38 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.